Internal Server Error

About Venrock

Venrock is a venture capital firm founded in 1969. It is primarily based out of Palo Alto, United States. As of Aug 2026, Venrock is an active investor, having invested in 441 companies, with 16 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series A round of Aligned Marketplace Overall, Venrock portfolio has seen 16 unicorns, 73 IPOs and 194 acquisitions including key companies like CloudFlare, athenahealth and Apple. A lot of funds co-invest with Venrock, with names like RA Capital Management sharing a substantial percentage of its portfolio. Venrock has team of 46 people including 16 partners.
Key Metrics
Portfolio Count
Portfolio Locations
Rounds of Entry
Series A, Series B & 9 more
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns

Venrock's List of Top Investments

Venrock has a portfolio of 441 companies, including 16 unicorns. Their most notable investments are in Angitia and Smartling.Their portfolio spans across United States, Canada, United Kingdom and 13 more locations. They have invested in Life Sciences, Enterprise Applications, High Tech and 35 other sectors, across stages such as Series A, Series B  and 9 more. Here is the list of top investments by Venrock:
Provider of cloud services for security, performance, and application development. The company delivers networking, security, and performance services through its connectivity cloud platform. It offers solutions for application security, application performance, and network services. The company's platform supports businesses in modernizing networks, securing workspaces, and optimizing web experiences.

Key facts about CloudFlare

  • Founded Year: 2009
  • Location: San Francisco (United States)
  • Annual Revenue: $1B+ as on Dec 31, 2025
  • Stage: Public
  • Total Funding till date: $332M
  • Employee Count: 7,284 as on May 31, 2026
  • Investors: HTIF, Fidelity Investments and 17 Others
  • Latest Funding Round: Post IPO, Aug 2021, $*****
  • Highlight: Public
Cloud-based administrative tool for healthcare providers. The company has developed EHR, practice management, and population health solutions. The features include EHR, practice management, revenue cycle management (RCM), patient engagement, population health services, care coordination, clinical decision support, and more.

Key facts about athenahealth

Technology company and product innovator developing consumer electronics. The firm designs smartphones, personal computers, tablets, wearables, and related hardware alongside proprietary operating systems and productivity applications. It provides integrated ecosystems including cloud computing, digital media distribution, payment processing, and enterprise software solutions. Services encompass content streaming platforms, mobile app marketplaces, augmented reality frameworks, and professional creative software suites. Continuous platform evolution maintains seamless hardware-software integration across personal computing and professional segments.

Key facts about Apple

Subscription-based anime streaming platform. It allows users to stream content under various categories, including anime series, shows, manga, drama, music, electronic entertainment, and more in various languages on multiple devices.

Key facts about Crunchyroll

  • Founded Year: 2006
  • Location: San Francisco (United States)
  • Stage: Acquired
  • Total Funding till date: $55.5M
  • Employee Count: 2,049 as on Jun 30, 2026
  • Investors: Venrock and TV TOKYO
  • Latest Funding Round: Series B, Aug 26, 2015, $*****
  • Highlight: Acquired
Gilead is a developer of medicines to treat HIV/AIDS, liver diseases, cancer & others. It is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. It has developed many medicines such as Lenacapavir capsid inhibitor (GS-6207) for HIV, Long-acting treatment: 2 bNAbs (GS-5423, GS-2872), Selgantolimod TLR-8 agonist (GS-9688), PD-L1 inhibitor (GS-4224) HBV cure, and many more. In 2022, the company recorded annual revenues of $27.28B and a net profit of $4.59B.

Key facts about Gilead

Venrock's Investments by Stage

Venrock has made 117 investments in Series A stage with an average round size of $21.4M, 82 investments in Series B stage with an average round size of $38M and 43 investments in Series C stage with an average round size of $65.3M.
Here are Venrock's investments by stage:
Stage of entry
No. of Investments
Series A
117
Series B
82
Series C
43
Seed
38
Post IPO
28
Others
41
Breakdown of Venrock's investments by stage of entrySeries A (117)Series B (82)
Note: We have considered here, only first round of investments

Venrock's Investments by Sector

Venrock has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, Enterprise Infrastructure, High Tech and Consumer. Notably, it has invested in 350 Tech companies, 328 Enterprise (B2B) companies, 155 Software companies and at least 67 companies focusing on Saas.
Here are Venrock's investments by sector:
Sector
No. of Investments
Life Sciences
138
Enterprise Applications
116
Enterprise Infrastructure
42
High Tech
42
Consumer
30
Others
248
Breakdown of Venrock's investments by sectorsLife Sciences (138)Enterprise Applic... (116)
Note: We have considered here, only first round of investments

Venrock's Investments by Geography

Venrock has made most investments in United States (317), followed by Canada where it has made 7 investments.
Here are Venrock's investments by geography:
Country
No. of Investments
United States
317
Canada
7
United Kingdom
6
China
5
Israel
4
Others
11
Breakdown of Venrock's investments by countriesUnited States (317)Canada (7)
Note: We have considered here, only first round of investments

Venrock's recent investments

Venrock has made 14 investments in 2026 so far. Aligned Marketplace and Expedition Therapeutics are the latest among them.
Here are the most recent investments by Venrock:
Date
Company
Location
Round Details
Round Amount
Co-Investors
Aug 14, 2026
United States
Series A
6171
-
Aug 05, 2026
United States
Series B
2672
Jul 24, 2026
United States
Series D
5904
Jun 25, 2026
United States
Series A
4676
May 20, 2026
United States
Series A
2381

Unicorns in Venrock's Portfolio

Venrock has 16 unicorns in its portfolio - SkyRyse, Element Biosciences, Altruist and others. The most recent unicorn in their portfolio is SkyRyse. It became a unicorn in 2026, 7 years after Venrock first invested in it.
Here is a list of unicorns in Venrock's portfolio:
Tracxn Score
Company
Short Description
Founded year
Sector
Location
Company Stage
First Investment/ Acquisition Details
65
Developer of advanced flight automation systems for aircraft
2016
Hayward
Series C
xvkfasy
64
Developer of benchtop DNA sequencer for research applications
2017
San Diego
Series E
zqkpdsy
70
Portfolio management software for financial advisors
2018
Culver City
Series F
x{nblfi
52
Developer of containerized launch system and small satellite launch vehicle
2017
El Segundo
Series B
zrqyahc
60
Provider of AI and ML-based intelligence systems
2019
Washington
Series B
mrrdmgc

IPOs and Publicly Listed companies in Venrock's Portfolio

73 of Venrock's portfolio companies have become public. Artiva got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2024 at marketcap of $211M and Alto Neuroscience got listed on the New York Stock Exchange (NYSE) at marketcap of $409M.
Here are Venrock's portfolio companies that went public:
Company
IPO Date
First Invested on
First Round of Investment
Round Size
Jul 19, 2024
Feb 22, 2021
Series B
8574
Feb 02, 2024
Mar 16, 2026
Post IPO
5313
Sep 12, 2023
Apr 19, 2022
Series A
2651
Feb 10, 2023
Feb 08, 2024
Post IPO
2603
Nov 01, 2021
Oct 29, 2020
Unattributed
6526

Acquired companies in Venrock's Portfolio

194 companies from Venrock's portfolio have been acquired. The most recent acquisition was Salsify in Jul 2026 by Cinven for $*****.
Here are Venrock's portfolio companies that got acquired most recently:
Company
Acquisition Date
First Invested on
First Round of Investment
Round Size
Jul 22, 2026
Jul 06, 2015
Series B
7495
Jun 22, 2026
Dec 07, 2022
Series B
7617
May 21, 2026
Apr 15, 2026
Series A
6151
May 03, 2026
Sep 09, 2024
Series D
5963
Apr 29, 2026
Jul 22, 2015
Post IPO
2812

Team profile of Venrock

Venrock has a team of 46 members including 16 Partners and 18 Principals located in United States. Venrock's team sits on the board of 5 companies.
Here is a list of top team members in Venrock:
Name
Designation
Location
Board Memberships
Contact Details
Partner
Palo Alto
Partner
Palo Alto
-
Partner
New York City
-
Partner
Palo Alto
-
Partner
New York City
-
Partner
New York City
-
-
Partner
Palo Alto
-
Partner
Palo Alto
-
Partner
Mountain View
-
-
Partner
Menlo Park
-
Partner
Menlo Park
-
-

Co-investors of Venrock

Over the past 50 years, 2075 investors have co-invested in Venrock's portfolio companies. This includes funds and angels.

  • Invested before VenrockRA Capital Management, HHS and 549 others have invested in rounds before Venrock. There are 10 companies where RA Capital Management has invested before Venrock and 9 companies where HHS has invested before Venrock.
  • Top Co-investors of Venrock659 investors entered a company along with Venrock. These include investors like RA Capital Management (22 companies).
  • Invested after VenrockA total of 865 investors have invested in Venrock's portfolio after their investments. Top Investors include Fidelity Investments (14 companies), SVB (13 companies) and Notable Capital (8 companies).

Recent News related to Venrock

View all news related to Venrock

FAQs about Venrock

Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford